Krystal Biotech reports $116.4M Q1 revenue, advances gene therapies with key FDA designations and upcoming trial readouts.

Krystal Biotech announced $116.4 million in global revenue for Q1 2026, a 32% increase year-over-year, driven by its gene therapy product VYJUVEK for dystrophic epidermolysis bullosa. The company completed enrollment in a key registrational study for KB803 and expects data readouts for KB803 and KB801 later in 2026. The FDA granted platform technology designations for KB407 and KB111, potentially accelerating development. Krystal ended the quarter with $1 billion in cash and investments, supporting ongoing trials and global expansion efforts.